Our study may partly reveal the deficiency of first‐line therapy and lay the foundation for the clinical application of cGAS‐STING pathway‐associated inhibitors in PTCL. The gene discussed is CGAS; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.